{"id":"W2892927588","doi":"10.1634/theoncologist.2018-0290","title":"A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"University of Texas MD Anderson Cancer Center; Central China Normal University","keywords":"Bevacizumab; Glioblastoma; Medicine; Oncology; Randomized controlled trial; Internal medicine; Chemotherapy; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001261686,0.0002109481,0.001065035,0.00003428177,0.0003057954,0.000009586312,0.0001109366,0.00007331678,0.00002855583],"category_scores_gemma":[0.002485898,0.00008162397,0.0003123368,0.0001235166,0.0009882044,0.00002383443,0.000069954,0.00005961884,0.000001679112],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001357382,"about_ca_system_score_gemma":0.000149125,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001959161,"about_ca_topic_score_gemma":0.0001891966,"domain_scores_codex":[0.9983188,0.0003457791,0.0006824803,0.0002418408,0.000199896,0.000211184],"domain_scores_gemma":[0.9940488,0.004688482,0.0005427637,0.0004040621,0.0002710382,0.00004480072],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8961071,0.004497379,0.00003184918,0.00002760646,0.0006180162,0.000002578805,0.002392475,0.000008377569,0.001690075,0.0002184743,0.0002192765,0.09418683],"study_design_scores_gemma":[0.8428766,0.1337048,0.000085982,0.0001314314,0.001773922,0.00001628971,0.0003521088,0.003117057,0.01553511,0.0001706169,0.002159986,0.00007612002],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9877545,0.001058861,0.00009844722,0.002538072,0.0003191296,0.00790017,0.00007994255,0.00002326024,0.000227649],"genre_scores_gemma":[0.9969385,0.0003012461,0.00123891,0.00005708643,0.0003956292,0.0009333403,0.00002012439,0.00001547209,0.00009970293],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1292074,"threshold_uncertainty_score":0.364108,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09663458954944744,"score_gpt":0.4254431738527606,"score_spread":0.3288085843033132,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}